GeneDx Holdings Corp. 8-K

What Happened

• On January 12, 2026, GeneDx Holdings Corp. filed a Form 8-K (Items 2.02 and 7.01) to announce preliminary, unaudited expectations for fourth-quarter and full-year 2025 results and to provide full-year 2026 guidance. The company disclosed expected preliminary revenue, exome and genome test result volumes, GAAP and adjusted gross margins for Q4 and FY2025, and cash, cash equivalents, marketable securities and restricted cash as of December 31, 2025. A press release and an investor presentation used at the J.P. Morgan Healthcare Conference were furnished as Exhibits 99.1 and 99.2.

Key Details

• Filing date: January 12, 2026 (Form 8-K; Items 2.02 and 7.01).
• Disclosed items: preliminary unaudited Q4 and FY2025 revenue expectations; exome and genome test result volumes for Q4 and FY2025; GAAP and adjusted gross margin for Q4 and FY2025; cash and equivalents as of Dec 31, 2025.
• Provided full-year 2026 financial guidance (details in attached press release and investor presentation).
• Materials furnished: Press Release (Exhibit 99.1) and Investor Presentation (Exhibit 99.2). The filing notes the furnished materials are not “filed” for purposes of Section 18 of the Exchange Act.

Why It Matters

• Investors get early, company-provided indicators of revenue, test volumes (demand), margins (profitability) and liquidity (cash position) for 2025 plus management’s outlook for 2026 — all items that can affect near-term stock expectations and analyst models.
• The results are described as preliminary and unaudited, so final audited figures could differ; the press release and investor deck contain the specific figures and guidance investors should review.
• The disclosure was furnished (not “filed”) under SEC rules, which limits certain legal liabilities associated with Section 18 filings.